MX2022005380A - Composiciones que comprenden colina. - Google Patents

Composiciones que comprenden colina.

Info

Publication number
MX2022005380A
MX2022005380A MX2022005380A MX2022005380A MX2022005380A MX 2022005380 A MX2022005380 A MX 2022005380A MX 2022005380 A MX2022005380 A MX 2022005380A MX 2022005380 A MX2022005380 A MX 2022005380A MX 2022005380 A MX2022005380 A MX 2022005380A
Authority
MX
Mexico
Prior art keywords
choline
single dose
dose form
compositions
cobalamin
Prior art date
Application number
MX2022005380A
Other languages
English (en)
Inventor
Jonathan Bortz
Original Assignee
Balchem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balchem Corp filed Critical Balchem Corp
Publication of MX2022005380A publication Critical patent/MX2022005380A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona una composición en forma de dosis individual para optimizar la relación entre las vías de "folato-cobalamina" y "colina-betaína". Las composiciones en forma de dosis individuales descritas en la presente aseguran una ingesta de los compuestos que limitan la velocidad que han demostrado que reducen la eficiencia de este eje metabólico vital, y los métodos para usarlo.
MX2022005380A 2016-03-22 2018-09-17 Composiciones que comprenden colina. MX2022005380A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662311590P 2016-03-22 2016-03-22

Publications (1)

Publication Number Publication Date
MX2022005380A true MX2022005380A (es) 2022-05-19

Family

ID=59900796

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011270A MX2018011270A (es) 2016-03-22 2017-03-20 Composiciones que comprenden colina.
MX2022005380A MX2022005380A (es) 2016-03-22 2018-09-17 Composiciones que comprenden colina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018011270A MX2018011270A (es) 2016-03-22 2017-03-20 Composiciones que comprenden colina.

Country Status (10)

Country Link
US (2) US11278591B2 (es)
EP (1) EP3432870A4 (es)
JP (1) JP2019510031A (es)
KR (1) KR20180121962A (es)
CN (1) CN109689035A (es)
AU (1) AU2017236879B2 (es)
BR (1) BR112018069285A2 (es)
CA (1) CA3018088A1 (es)
MX (2) MX2018011270A (es)
WO (1) WO2017165287A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027738A1 (en) 2015-08-11 2017-02-16 Akeso Biomedical, Inc. Antimicrobial preparation and uses thereof
US10653658B2 (en) * 2015-08-11 2020-05-19 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
CN109438268B (zh) * 2018-10-18 2021-08-03 济南蓬勃生物技术有限公司 一种酒石酸氢胆碱及其制备方法
USD886143S1 (en) 2018-12-14 2020-06-02 Nutanix, Inc. Display screen or portion thereof with a user interface for database time-machine
US10817157B2 (en) 2018-12-20 2020-10-27 Nutanix, Inc. User interface for database management services
US11010336B2 (en) 2018-12-27 2021-05-18 Nutanix, Inc. System and method for provisioning databases in a hyperconverged infrastructure system
US11816066B2 (en) 2018-12-27 2023-11-14 Nutanix, Inc. System and method for protecting databases in a hyperconverged infrastructure system
US11604705B2 (en) 2020-08-14 2023-03-14 Nutanix, Inc. System and method for cloning as SQL server AG databases in a hyperconverged system
US11907167B2 (en) 2020-08-28 2024-02-20 Nutanix, Inc. Multi-cluster database management services
US11640340B2 (en) 2020-10-20 2023-05-02 Nutanix, Inc. System and method for backing up highly available source databases in a hyperconverged system
US11604806B2 (en) 2020-12-28 2023-03-14 Nutanix, Inc. System and method for highly available database service
US11892918B2 (en) 2021-03-22 2024-02-06 Nutanix, Inc. System and method for availability group database patching
GB202112170D0 (en) * 2021-08-25 2021-10-06 Mitocholine Ltd Nutritional compositions
US11803368B2 (en) 2021-10-01 2023-10-31 Nutanix, Inc. Network learning to control delivery of updates

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087517A (zh) * 1992-09-14 1994-06-08 韦斯塔药品有限公司 用于降低高半胱氨酸水平的药物制剂
WO1994009769A1 (en) 1992-11-02 1994-05-11 Buchman Alan L Use of choline in total parenteral nutrition
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
US20040086564A1 (en) * 2002-10-31 2004-05-06 Richardson Paul H. Dosage forms containing stabilized choline and method for preparing same
US7429569B2 (en) 2004-01-29 2008-09-30 Fast Balance, Inc. Compositions and methods for the regulation of homocysteine levels within the body
US20090035385A1 (en) * 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
MX2009003658A (es) * 2006-10-05 2009-04-22 Cv Therapeutics Inc Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
MA33899B1 (fr) * 2009-12-08 2013-01-02 Hemaquest Pharmaceuticals Inc Procedes et regimes a faible dose pour des troubles des globules rouges
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
US20140271983A1 (en) * 2013-03-15 2014-09-18 Eduardo Fernandez Gummy compositions for nutritional supplementation
US20150132273A1 (en) * 2013-11-09 2015-05-14 Rhett Sean Daniels Nutritional Compositions and Methods for Treating Cognitive Impairment
BR112019011310A2 (pt) * 2016-12-09 2019-10-15 Balchem Corp nutrientes essenciais e métodos relacionados

Also Published As

Publication number Publication date
US20220160830A1 (en) 2022-05-26
BR112018069285A2 (pt) 2019-01-22
EP3432870A4 (en) 2019-11-20
KR20180121962A (ko) 2018-11-09
US20190125828A1 (en) 2019-05-02
WO2017165287A1 (en) 2017-09-28
AU2017236879B2 (en) 2022-07-21
CN109689035A (zh) 2019-04-26
MX2018011270A (es) 2019-07-08
JP2019510031A (ja) 2019-04-11
EP3432870A1 (en) 2019-01-30
AU2017236879A1 (en) 2018-10-11
CA3018088A1 (en) 2017-09-28
US11278591B2 (en) 2022-03-22

Similar Documents

Publication Publication Date Title
MX2022005380A (es) Composiciones que comprenden colina.
PH12018501226A1 (en) Methods for treating huntingtons disease
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
CR20200228A (es) COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554)
MX2018003926A (es) Composicion para mejorar el rendimiento.
MX2019005082A (es) Composiciones que comprenden 15-ohepa y metodos para usar las mismas.
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
PH12017500737B1 (en) Kcnq2-5 channel activator
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
GEP20186893B (en) Pyrazines modulators of gpr6
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
PH12015502727A1 (en) Methods and compositions for enhancing cognitive performance
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
IN2013MU03428A (es)